Luo Xiao-Yang, Chen Hai-Quan, Sun Yi-Hua, Zhou Jian-Hua, Wang Wen-Fing, Liao Ping, Xiang Cui-Qin
Department of Cardiothoracic Surgery, Shanghai Jiaotong University No. 6 People's Hospital, Shanghai 200233, China.
Zhonghua Zhong Liu Za Zhi. 2006 Dec;28(12):907-10.
To screen relatively specific biomarkers in serum from lung adenocarcinoma patients by surface-enhanced laser desorption and ionization time of flight mass spectrometry (SELDI-TOFMS), and to investigate the clinical value of SELDI-TOF-MS in differentiation of benign from malignant solitary pulmonary nodules (SPN).
Serum samples from 71 lung adenocarcinoma patients and 71 healthy volunteers with matched gender, age and history of smoking were analyzed using WCX2 ProteinChip to screen potential biomarkers. 28 patients received surgical treatment among total 53 patients with SPN. The clinical value of SELDI-TOF-MS in differentiation of benign from malignant solitary pulmonary nodules was evaluated by pathological diagnosis.
Five highly expressed potential biomarkers were identified with the relative molecular weights of 4047.79 Da, 4203.99 Da, 4959. 81 Da, 5329. 30 Da and 7760.12 Da. The postoperative pathologic diagnosis was lung adenocarcinoma in 24 patients with SPN, validating the clinical value of the 5 potential biomarkers.
SELDI-TOF-MS technology is a quick, easy, convenient, and high-throughput analyzing method capable of screening several relatively specific potential biomarkers from the serum of lung adenocarcinoma patients and may have attractive clinic value in differentiation of solitary pulmonary nodules.
通过表面增强激光解吸电离飞行时间质谱（SELDI-TOFMS）技术筛选肺腺癌患者血清中相对特异的生物标志物，探讨SELDI-TOF-MS技术在鉴别孤立性肺结节（SPN）良恶性中的临床价值。
采用WCX2蛋白芯片分析71例肺腺癌患者及71例性别、年龄、吸烟史相匹配的健康志愿者的血清样本，筛选潜在生物标志物。53例SPN患者中28例接受了手术治疗，通过病理诊断评估SELDI-TOF-MS技术在鉴别SPN良恶性中的临床价值。
鉴定出5个相对分子质量分别为4047.79Da、4203.99Da、4959.81Da、5329.30Da和7760.12Da的高表达潜在生物标志物。24例SPN患者术后病理诊断为肺腺癌，验证了这5个潜在生物标志物的临床价值。
SELDI-TOF-MS技术是一种快速、简便、高通量的分析方法，能够从肺腺癌患者血清中筛选出多个相对特异的潜在生物标志物，在孤立性肺结节鉴别诊断中可能具有重要临床价值。
